GlassScriptPhysician profile
Kevin Myers
NPI 1235588658
$11,334.20
in general payments reported to CMS, 2019-2025
27 companies · $1,994 in 2025
The $1,994 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,404 · 2020: $2,223 · 2021: $1,016 · 2022: $1,204 · 2023: $1,403 · 2024: $2,089 · 2025: $1,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,421 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,421.49 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,428.58 | 2019-2025 | |
| Amgen INC. | $1,789.23 | 2020-2025 | Otezla, Otezla |
| Lilly USA, LLC | $942.37 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $832.31 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $814.97 | 2019-2025 | Aklief, Dysport, Nemluvio |
| Janssen Biotech, INC. | $696.05 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $621.59 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $524.76 | 2019-2025 | Odomzo, Blu-U, Ilumya |
| Dermavant Sciences, INC. | $431.84 | 2023-2024 | Vtama |
| Pfizer INC. | $341.92 | 2021-2025 | |
| Genzyme Corporation | $331.75 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $285.56 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $183.88 | 2021-2025 | Libtayo, Dupixent |
| Biofrontera INC. | $183.68 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $169.75 | 2021-2025 | Vtama, Nexplanon |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $141.91 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $134.85 | 2019-2023 | Jublia |
| Incyte Corporation | $127.64 | 2022-2023 | Opzelura |
| Leo Pharma INC. | $109.25 | 2019-2025 | Adbry |
| Genentech USA, INC. | $74.48 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $47.76 | 2024-2025 | Sotyktu |
| Biowound Solutions, INC. | $28.99 | 2025 | Bio-Connekt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.55 | 2022 | |
| Vyne Pharmaceuticals INC. | $20.97 | 2021 | |
| Boston Scientific Corporation | $18.66 | 2022 | |
| Journey Medical Corporation | $16.03 | 2025 | |
| Kerecis Limited | $13.87 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.